INOVIO and Akeso Partner to Test Novel Glioblastoma Combination Therapy
Event summary
- INOVIO and Akeso will collaborate on a Phase 2 trial combining INO-5412 with cadonilimab for glioblastoma (GBM).
- The trial will be part of the INSIGhT platform study sponsored by Dana-Farber Cancer Institute.
- Dosing in the combination therapy trial is expected to begin in the second half of 2026.
- Cadonilimab, Akeso's PD-1/CTLA-4 bispecific antibody, has received marketing approval in China for multiple cancer indications.
The big picture
This collaboration represents a strategic push into the highly challenging glioblastoma space, where few effective treatments exist. The combination of INOVIO's DNA immunotherapy with Akeso's bispecific antibody could address a critical unmet need, particularly if the trial demonstrates enhanced survival benefits. The partnership also underscores the growing trend of cross-border biotech collaborations to accelerate drug development.
What we're watching
- Clinical Efficacy
- Whether the combination of INO-5412 and cadonilimab can demonstrate superior efficacy in GBM patients compared to existing treatments.
- Regulatory Pathway
- The pace at which the trial results could lead to regulatory approvals, particularly given cadonilimab's existing approvals in China.
- Commercial Strategy
- How INOVIO and Akeso plan to leverage this collaboration to expand their respective pipelines and market reach in oncology.
Related topics